Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Project SilverOncology Center of Excellence Project Silver
  
  					Improving the Evidence Base for the Treatment of Older Adults with Cancer
	
    Share
    Post
    Linkedin

    Email
    PrintImage
              Project Silver**Purpose**

Project Silver is a public health initiative established by the FDA Oncology Center of Excellence (OCE) to increase representation of older adults (65 years and older) in cancer clinical trials with the goal of improving their treatment, care, and outcome through evidence base data.

**Why is this important?**

Clinical trials are the key step in advancing potential new cancer treatments from the research setting to the cancer care clinic. Differences may exist between younger and older patients in drug response and toxicity.  Also, older adults often have several health conditions requiring medications that could impact efficacy or the incidence and severity of adverse events.

Adults 65 years and older are a growing segment of the oncology population. Cancer incidence is expected to increase by 67% from 2010 to 2030 in people age 65 and older. Given the aging U.S. population, it’s particularly important now more than ever to ensure that older adults are also enrolling in cancer clinical trials. Adequate representation of older adults who share a disproportionate burden of the cancer disease will allow generalizability of trial results which can then be conveyed to patients and health care providers.

*However, older adults—particularly adults 75 years and older—have been historically underrepresented in clinical trials.*

**Project Silver Initiatives**

**Regulatory Policy**

Encourage sponsors to conduct inclusive and representative trials early in development
	Evaluate regulatory submissions for data in age subgroups
	Consider need for additional data post approval
	Develop Guidance for Industry**Science and Research**

Actively engage in scientific collaboration with clinicians, social scientists and statisticians across FDA
	Evaluate geriatric assessment tools and other measures for physiologic age
	Foster opportunities for FDA oncology reviewers related to geriatric oncology**Global Engagement**

Engage with global regulatory agencies to identify global strategies to increase evidence base for older adults
	Collaborate with global regulatory agencies through Project Orbis on review of demographic age subgroup information in applications and prescribing information**Advocacy and Outreach**

Engage with patient advocacy groups to assess opportunities to improve clinical trial enrollment
	Identify inclusive clinical trial opportunities including decentralized trials, etc.
	Engage with older adults to understand treatment goals and outcomes**Meet the Team**

**Project Lead**: Harpreet Singh, MD, Associate Director, Oncology in Older Adults and Special Populations, Oncology Center of Excellence

**Clinical Team Lead**: Bindu Kanapuru, MD, Division of Hematological Malignancies II, Office of Oncologic Diseases, Center for Drug Evaluation and Research

**Project Management:**Pamela Balcazar, MS, Health Scientist, Oncology Center of Excellence

**Select Events**

FDA has sponsored multiple public workshops to further engage with the stakeholders and the broader community on the importance of diverse representation in cancer clinical trials.

**November 6, 2017**:FDA-ASCO Public Workshop: Geriatric Oncology Workshop | FDA
	**Part 1 January 22, 2021, Part 2 January 25, 2021, Part 3 January 27, 2021**:Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer A Workshop | National Academies
	**March 23, 2021:** Roadmap to 2030 for New Drug Evaluation in Older Adults - 03/23/2021 - 03/23/2021 | FDA**FDA Guidance Documents**

*Inclusion of Older Adults in Cancer Clinical Trials (March 2020)*
	*Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs*
	*Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections*
	*Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies*
	*Guideline for the Study of Drugs Likely to be Used in the Elderly*
	*Studies in Support of Special Populations: Geriatrics ICHE7*
	*Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Indust*ry**Select Publications**

*Harpreet S., Kanapuru B., Smith Che, Fashoyin-Aje L., Myers A., Kim G., and Pazdur, R**.*FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration. Journal of Clinical Oncology 2017 35:15_suppl, 10009-10009
	*Kanapuru B., Harpreet S., Myers A., Beaver, J., Kwitkowski, V., Farrell, A., and Pazdur, R.* Enrollment of Older Adults in Clinical Trials Evaluating Patients with Hematologic Malignancies - the Food and Drug Administration (FDA) Experience Blood, Volume 130, Supplement 1, 2017, Page 861
	*Levit LA, Singh H, Klepin HD, Hurria A.* Expanding the Evidence Base in Geriatric Oncology: Action Items From an FDA-ASCO Workshop  J Natl Cancer Inst. 2018 Nov 1;110(11):1163-1170. doi: 10.1093/jnci/djy169.
	*Kanapuru B, Singh H, Kwitkowski V, Blumenthal G, Farrell AT, Pazdur R.* Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation Blood Rev. 2020 Sep;43:100670. doi:10.1016/j.blre.2020.100670
	*Singh H, Beaver JA, Kim G, Pazdur R.*Enrollment of older adults on oncology trials: An FDA perspective J Geriatr Oncol. 2017 May;8(3):149-150. doi: 10.1016/j.jgo.2016.11.001. Epub 2016 Dec 23
	Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer: Proceedings of a Workshop – in Brief \ Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer: Proceedings of a Workshop-in Brief \ The National Academies Press nap.edu

                                                                                  Content current as of:
      10/05/2021Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop